A prospective, multinational, multicenter, randomized, sequential, double-blind, placebo-controlled, phase 2a clinical study to assess the safety and pharmacokinetics (PK) of OMN6 in hospital-acquired bacterial pneumonia (HABP) or ventilated-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC).

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524200-29-00

Enrollment

Registered

2026-05-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hospital-acquired bacterial pneumonia or ventilated-associated bacterial pneumonia caused by Acinetobacter baumannii complex.

Brief summary

Incidence of TEAE and SAEs by frequency, severity, relatedness, and outcome, clinical laboratory findings, vital signs and ECGs change from baseline and 28-day ACM., OMN6 PK parameters.

Detailed description

Proportion of participants with clinical cure, clinical improvement, combined clinical cure plus clinical improvement.

Interventions

DRUGSALINE

DRUGOMN6

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of TEAE and SAEs by frequency, severity, relatedness, and outcome, clinical laboratory findings, vital signs and ECGs change from baseline and 28-day ACM., OMN6 PK parameters.	—

Secondary

Measure	Time frame
Proportion of participants with clinical cure, clinical improvement, combined clinical cure plus clinical improvement.	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 8, 2026